2024
The Effects of Shaoma Zhijing Granules and its Main Components on Tourette Syndrome
Zhao Q, Hu Y, Yan Y, Song X, Yu J, Wang W, Zhou S, Su X, Bloch M, Leckman J, Chen Y, Sun H. The Effects of Shaoma Zhijing Granules and its Main Components on Tourette Syndrome. Phytomedicine 2024, 129: 155686. PMID: 38759346, DOI: 10.1016/j.phymed.2024.155686.Peer-Reviewed Original ResearchTourette syndromeChina National Knowledge Infrastructure (CNKI) databasesNerve damageRepair of nerve damageClinical trialsEffective treatmentImprove sleep disordersNeurotransmitter imbalanceSleep disordersReducing neuroinflammationSyndromeComprehensive searchClinical applicationChinese medicine compoundObsessive-compulsive disorder
2019
Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial
Shannahoff-Khalsa D, Fernandes RY, de B. Pereira C, March JS, Leckman JF, Golshan S, Vieira MSR, Polanczyk GV, Miguel EC, Shavitt RG. Kundalini Yoga Meditation Versus the Relaxation Response Meditation for Treating Adults With Obsessive-Compulsive Disorder: A Randomized Clinical Trial. Frontiers In Psychiatry 2019, 10: 793. PMID: 31780963, PMCID: PMC6859828, DOI: 10.3389/fpsyt.2019.00793.Peer-Reviewed Original ResearchY-BOCS scoresFirst-line therapyObsessive-compulsive disorderClinical trialsSecondary measuresY-BOCSShort Form-36 Health SurveyBaseline Y-BOCS scoresCompulsive ScaleGreater improvementRelative efficacyClinical Global ImpressionEffective treatment scheduleYale-Brown Obsessive Compulsive ScaleHigh psychosocial impairmentBeck Depression InventoryBeck Anxiety InventoryLife-long disorderObsessive Compulsive ScaleYale-Brown ObsessiveYoga meditationLine therapyPrimary outcomeTreat analysisReuptake inhibitors
2017
Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum
Frick L, Rapanelli M, Jindachomthong K, Grant P, Leckman JF, Swedo S, Williams K, Pittenger C. Differential binding of antibodies in PANDAS patients to cholinergic interneurons in the striatum. Brain Behavior And Immunity 2017, 69: 304-311. PMID: 29233751, PMCID: PMC5857467, DOI: 10.1016/j.bbi.2017.12.004.Peer-Reviewed Original ResearchConceptsGroup A beta-hemolytic streptococciCholinergic interneuronsPediatric Autoimmune Neuropsychiatric Disorder AssociatedNeuropsychiatric Disorder AssociatedStriatal cholinergic interneuronsStriatum of miceBeta-hemolytic streptococciBrain antigensPANDAS patientsIntravenous immunoglobulinStriatal interneuronsNeuropsychiatric symptomsObsessive-compulsive disorderSymptom improvementGABAergic interneuronsClinical trialsHealthy controlsDisorders AssociatedTic disordersChildhood onsetInterneuronsLocus of pathologyElevated bindingAntibodiesStriatum
2012
Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition
Qawasmi A, Landeros-Weisenberger A, Leckman JF, Bloch MH. Meta-analysis of Long-Chain Polyunsaturated Fatty Acid Supplementation of Formula and Infant Cognition. Pediatrics 2012, 129: 1141-1149. PMID: 22641753, PMCID: PMC3362904, DOI: 10.1542/peds.2011-2127.Peer-Reviewed Original ResearchConceptsLCPUFA supplementationClinical trialsInfant formulaLong-Chain Polyunsaturated Fatty Acid SupplementationBayley ScalesPolyunsaturated Fatty Acid SupplementationTrial methodologic qualityInfants fed formulaWeighted mean differenceSecondary subgroup analysisFatty acid supplementationMeasures of neurodevelopmentInfant Development scoresFed formulaPrimary outcomeSubgroup analysisUnsupplemented formulaMethodologic qualityInclusion criteriaPrematurity statusAcid supplementationSupplementation efficacySecondary analysisPublication biasMean difference
2011
Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13
Tobiasova Z, van der Lingen KH, Scahill L, Leckman JF, Zhang Y, Chae W, McCracken JT, McDougle CJ, Vitiello B, Tierney E, Aman MG, Arnold LE, Katsovich L, Hoekstra PJ, Volkmar F, Bothwell AL, Kawikova I. Risperidone-Related Improvement of Irritability in Children with Autism Is not Associated with Changes in Serum of Epidermal Growth Factor and Interleukin-13. Journal Of Child And Adolescent Psychopharmacology 2011, 21: 555-564. PMID: 22070180, PMCID: PMC3279715, DOI: 10.1089/cap.2010.0134.Peer-Reviewed Original ResearchConceptsMedication-free subjectsEpidermal growth factorHealthy controlsInflammatory markersIL-13IL-1 receptor antagonistGrowth factorSerum inflammatory markersChemoattractant protein-1Placebo groupClinical improvementBaseline visitIL-17Serum levelsCytokine concentrationsInflammatory moleculesSerum concentrationsClinical trialsHealthy subjectsIL-1Interleukin-13RisperidoneAltered levelsProtein 1Diagnosis of autism
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptomsMeta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder
Bloch MH, McGuire J, Landeros-Weisenberger A, Leckman JF, Pittenger C. Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder. Molecular Psychiatry 2009, 15: 850-855. PMID: 19468281, PMCID: PMC2888928, DOI: 10.1038/mp.2009.50.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsY-BOCS scoresSerotonin reuptake inhibitorsObsessive-compulsive disorderHigh dosesReuptake inhibitorsTreatment respondersDose of SSRIsTreatment efficacyDouble-blind placebo-controlled clinical trialGreater side effect burdenPlacebo-controlled clinical trialSide effect burdenAbsolute risk differenceTreatment of adultsGreater treatment efficacyMajor depressive disorderImproved treatment efficacyTreatment of OCDDose-response relationshipRevMan 4.2.8Clinical trialsDepressive disorderCause dropoutsMean change
2007
Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania
Bloch MH, Landeros-Weisenberger A, Dombrowski P, Kelmendi B, Wegner R, Nudel J, Pittenger C, Leckman JF, Coric V. Systematic Review: Pharmacological and Behavioral Treatment for Trichotillomania. Biological Psychiatry 2007, 62: 839-846. PMID: 17727824, DOI: 10.1016/j.biopsych.2007.05.019.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsHabit reversal therapyTreatment of trichotillomaniaCochrane Central RegisterPrimary outcome measureClinical rating scalesNon-specific effectsSSRI pharmacotherapyCentral RegisterControlled TrialsRelevant trialsReuptake inhibitorsTreat analysisPharmacotherapy studiesBlinded assessmentClinical trialsTrichotillomania severityMean changeOutcome measuresFuture therapiesElectronic databasesLarger sample sizeRigorous control conditionsPsychiatric conditionsSystematic review
2006
Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome
Mink JW, Walkup J, Frey KA, Como P, Cath D, DeLong MR, Erenberg G, Jankovic J, Juncos J, Leckman JF, Swerdlow N, Visser‐Vandewalle V, Vitek JL. Patient selection and assessment recommendations for deep brain stimulation in Tourette syndrome. Movement Disorders 2006, 21: 1831-1838. PMID: 16991144, DOI: 10.1002/mds.21039.Peer-Reviewed Original ResearchConceptsDeep brain stimulationTourette syndromeClinical trialsBrain stimulationClinical treatment choiceFuture clinical trialsTourette Syndrome AssociationEarly clinical experiencePotential clinical trialsSurgical candidatesPatient selectionTreatment choiceTic disordersSyndrome AssociationClinical careAlternative treatmentClinical experienceTic severityEarly useSyndromeAssessment recommendationsTrialsRecent publicityStimulationSurgery
2003
Tourette’s syndrome in children
Swain JE, Leckman JF. Tourette’s syndrome in children. Current Treatment Options In Neurology 2003, 5: 299-308. PMID: 12791197, DOI: 10.1007/s11940-003-0036-6.Peer-Reviewed Original ResearchTourette syndromeSide effectsComorbid conditionsPharmacologic agentsCourse of ticsLow-dose neurolepticsRealistic treatment expectationsAvailable pharmacologic agentsAttention deficit hyperactivity disorderBenefits of interventionsCommitted cliniciansDeficit hyperactivity disorderObsessive-compulsive disorderTreatment optionsSuccessful treatmentClinical trialsSomatic treatmentsTreatment responseSpecific symptomsEffective treatmentCommon treatmentTreatment expectationsTic severityTic controlNeurophysiologic basis
2001
Tic disorders: when habit forming neural systems form habits of their own?
Leckman JF, Yeh CB, Cohen DJ. Tic disorders: when habit forming neural systems form habits of their own? Journal Of The Chinese Medical Association 2001, 64: 669-92. PMID: 11922487.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderTourette syndromeAttention-deficit/hyperactivity disorderBasal gangliaIntolerable side effectsSubgroup of patientsLong-term outcomesAlpha-adrenergic agentsMajor affective disordersSpecific brain circuitsNew therapeutic directionDeficit/hyperactivity disorderAutoimmune mechanismsEarly brain developmentComorbid conditionsAtypical neurolepticsClinical neuroscience researchClinical trialsPrevalent disorderChildhood onsetClinical careMarked impairmentSide effectsPharmacological techniquesAffective disorders
1991
Clonidine Treatment of Gilles de la Tourette's Syndrome
Leckman JF, Hardin MT, Riddle MA, Stevenson J, Ort SI, Cohen DJ. Clonidine Treatment of Gilles de la Tourette's Syndrome. JAMA Psychiatry 1991, 48: 324-328. PMID: 2009034, DOI: 10.1001/archpsyc.1991.01810280040006.Peer-Reviewed Original ResearchConceptsGilles de la Tourette's syndromeLa Tourette's syndromeClonidine treatmentTourette syndromeTic severityDouble-blind clinical trialMotor tic severityClinical trialsClonidine hydrochlorideBehavioral symptomsClinical ratingsSyndromeMagnitude of responseClonidineTreatmentParent-rated measuresSeveritySubjectsPlaceboVideotaped interviewGroupSymptomsCliniciansHyperactivityTrials